

Index

(IUGR = intrauterine growth restriction; HCG = human chorionic gonadotrophin; AFP = alpha fetoprotein; SGA = small for gestational age)

- Abdominal circumference 2
- Abdominal decompression 316–17
- Acidosis 176
- Acquired immunodeficiency syndrome 44
- Activated protein C resistance 300–1
- Activators 107–9
- Activins 115
 - as marker of fetoplacental growth restriction 251
- Adhesion proteins 92
- Adult health, IUGR and 367–84
 - developmental stage and effect 375–6
 - fetal growth and adult cardiovascular disease 368–70
 - coronary heart disease 368–9
 - raised blood pressure and hypertension 369–70
 - influences on fetal programming 376–80
 - determinants of fetal growth 376
 - dietary balance and maternal body composition 379–80
 - effects on fetal proportions 379
 - fetal growth trajectory 377–8
 - intergeneration effects on fetal growth 378
 - maternal nutrition 376–7
 - paradoxical effects on placental growth 378–9
 - mechanisms 373–5
 - adrenocortical and sympathoadrenal hormonal activity 373–5
 - skeletal muscle metabolism 373
 - metabolic and endocrine disease 370–3
 - cholesterol metabolism and blood coagulation 372
 - non-insulin-dependent diabetes and insulin resistance 370–1
 - polycystic ovary syndrome 372–3
 - programming during early development 367–8
- Alcohol
 - effects on fetal growth 60–1, 361
 - placental transfer 181
- Alpha fetoprotein 239–43, 247–9
 - biology 239–40
 - high maternal
 - and diseases of pregnancy 240–2
 - and fetal anomalies 240
 - pathophysiology of 243
- Amino acids 75
 - intra-amniotic infusion 310–11
 - placental transfer 177–80
- Amniotic fluid 223–4
 - volume 266–7, 277–8
- Amniotic fluid index 262, 277
- Amphetamines, effects on fetal growth 63
- Anaemia, maternal 340, 341
 - and IUGR 293
- Anencephaly, and high maternal AFP 242
- Aneuploidy 258–9
 - sex chromosome 18
- Angiopoietins 158–9
- Angiotensin II 112
- Animal studies 73–88
 - animal models 81–5
 - programming and critical periods 81–5
 - species 81
 - determinants of fetal growth 73–80
 - endocrine/paracrine factors 75–9
 - environmental factors 79–80
 - genetic factors 79
 - infection 79
 - nutrients 73–5
 - plurality 79
 - temperature 79
 - duration and severity of insult 85–6
 - experimental measurement of fetal growth rate 80
 - knockout mice 387–8, 395
- Antenatal care 308–12
 - dietary supplementation 309–11
 - drug abuse during pregnancy 311–12
 - physical activity 312
- Antepartum cardiotocography 279
- Antepartum fetal death 323–35
 - after delivery and follow-up 332
 - investigations 328–32
 - cytogenetics 330
 - placental pathology 331–2
 - postmortem 330–1
 - thrombophilia screening 329–30
 - obstetric management 324–8
 - Caesarean section 328
 - complications of fetal death 325–6

- Antepartum fetal death—*continued*
 diagnosis 324–5
 induction of labour 326–8
 timing of delivery 325
 twin intrauterine death 328
- Antepartum tests 277–84
 amniotic fluid volume 277–8
 biophysical profile score 281–2
 Doppler ultrasound 282–4
 fetal heart rate monitoring 279–81
- Anticardiolipin antibody 298
- Antiphospholipid autoantibodies 298–9
- Antithrombin III 300
- Apgar score 339
- Arabinoside 38
- Aspirin, low dose, in treatment of IUGR 312–13
- Assymmetric growth restriction 342
- Asthma, maternal, and IUGR 293
- Bayes' theorem 404–6
- Beckwith-Wiedemann syndrome 21
- Benzodiazepines, and fetal growth 63
- Beta-adrenoceptor antagonists, and fetal growth 55–6
- Biochemical markers 239–56
 activin A 251
 AFP 239–43, 247–9
 cytokines 252
 fibronectin 250–1
 growth factors 251
 HCG 243–9
 inhibin A 251
 isoferritin 252
 prostacyclin 250
 unconjugated oestriol 250
- Biometry
 identification of IUGR fetus by 219–21
 prediction of adverse outcome by 221–3
- Biophysical profile score 281–2
- Biparietal diameter 208–9, 210
- Birthweight
 charts 214, 215
 cohort studies 351–2
 for gestational age 1–2
 matching for in case-control studies 352
see also Small for gestational age infants
- Blood coagulation, in adulthood, and fetal growth 372
- Blood group antigens 117
- Bloom syndrome 23
- Bone growth disturbance 23
- Brain sparing 217, 313, 343
- Branching angiogenesis 150
- Cabergoline 332
- Cadherins 93, 102–3
- Caesarean section 286–8
 antepartum fetal death 328
 rates and complications 286–7
 in SGA fetus 287
- Cannabis, effects on fetal growth 63
- Carbohydrates 74–5
- Carbon dioxide, placental transfer 174–5
- Carbon monoxide, effects on fetus 59
- Cardiac disease, maternal, and IUGR 293
- Carrier-mediated active transport 171
- Cell adhesion molecules 91–7
 cadherins 93
 expression by cytotrophoblast 102–3
 extracellular matrix 91–3
 immunoglobulins 93, 95
 integrins 95–7
 and oxygen tension 104–5
 and pre-eclampsia 103–4
 selectins 95
 in trophoblast invasion 97–9
- Cell islands 117
- Cerebral palsy 359–60
- Chicken pox 42
see also Varicella
- Cholesterol metabolism, in adulthood, and fetal growth 372
- Chorion villus sampling 11
- Chorionic plate 118
- Chromosomal analysis 330
- Chromosome abnormalities 8–10, 258
 confined placental mosaicism 10–18, 22
 monosomy X (Turner syndrome) 10
 mosaicism 10
 placental 193
 screening for 223
 triploidy 9, 258
 trisomies and structural abnormalities 8–9, 18–22, 258
 uniparental disomy 10–18
- Cigarette smoking *see* Smoking
- Circumvallate placentation 188
- Clinical trials 407–12
 matching 408
 meta-analysis 412
 randomised controlled trials 408
 reasons for having 407–8
 sources of bias 409–10
 biased assessment of outcome 409
 co-interventions 410
 placebo effect 409–10
 postrandomisation exclusions 409
 statistical problems of 410–11
 avoidance of type 1 error 410
 multiple tests of significance 411
 odds ratios and confidence intervals 411
 type 2 error 411
- Coagulation proteins 299–301
- Cocaine
 and fetal growth 62
 placental transfer 181
- Cockayne syndrome 23
- Cohort studies
 birthweight 351–2
 preterm infants 357–9

- term infants 354–7
- very preterm infants 357–9
- Collagenase
 - interstitial 105–6
 - type IV 106
- Confidence intervals 411
- Confined placental mosaicism 10–18, 395–6
- Congenital anomalies 360
 - see also* Chromosome abnormalities
- Congenital rubella syndrome 40
- Congenital varicella syndrome 42
- Connexins 114
- Contraction stress test 269
- Coronary heart disease, and fetal growth 368–9
- Corticosteroids
 - and fetal growth 52–3
 - in treatment of IUGR 317
- Cortisol, and fetal growth 76–7
- Crown-rump length 208, 209
 - and trisomies 8–9
- Cyclosporin, and fetal growth 54–5
- Cytokeratins 91
- Cytokines 113
 - as marker of fetoplacental growth restriction 252
- Cytomegalovirus 32–9
 - congenital 34–5
 - diagnosis 33–4, 37
 - prevention 38–9
 - prognosis 34–5
 - symptoms
 - in adults 32
 - in neonate 35, 37
 - transmission of 34
 - treatment 38
- Cytosine arabinoside 38
- Cytotrophoblast 12
 - development 389–90
 - expression of cell adhesion molecules by 102–3
 - intravascular extravillous 190
 - invasion 99–101
 - migration 98–9
 - proliferation 97–9
 - and cell adhesion molecules 102–3
 - and oxygen tension 104–5
 - and pre-eclampsia 103–4
 - switching of integrin repertoires 99–101
- de Lange syndrome 23
- Definitions 1–4
- Designer drugs, effects on fetal growth 63
- Determinants of fetal growth 73–80
 - endocrine/paracrine factors 75–9
 - cortisol 76–7
 - insulin 76
 - insulin-like growth factors 77–8
 - pituitary hormones 77
 - thyroid hormones 76
 - environmental factors 79–80
 - maternal nutrition 80
 - maternal size 79–80
- genetic factors 79
- infection 79
- nutrients 73–5
 - amino acids 75
 - carbohydrates 74–5
 - lipids 75
 - oxygen 74
- plurality 79
- temperature 79
- Diabetes
 - in adulthood, and fetal growth 370–2
 - maternal, and IUGR 293
- Diagnosis of IUGR 257–60, 309
 - differential 257–60
 - aneuploidy 258–9
 - healthy small fetus 257–8
 - placental IUGR 259
 - invasive procedures 259–60
 - ultrasound 3–4
- Diandry 9
- Dietary supplementation 310–11
- Diffusion 169–71
 - electrical gradients 171
 - facilitated 171
 - paracellular 170–1
- Digyny 9
- Disseminated intravascular coagulation 324, 325
- Donohue syndrome 23
- Doppler ultrasound *see* Ultrasound, Doppler
- Double trisomies 18
- Down's syndrome, and high maternal HCG 244
- Drug abuse 56–64
 - alcohol 60–1
 - amphetamines 63
 - benzodiazepines 63
 - cannabis 63
 - cocaine 62
 - designer drugs 63
 - nicotine 57–60
 - opiates 61–2
 - placental transfer 181
 - pregnancy management 63–4, 311–12
 - volatile substances 63
- Drugs
 - therapeutic 51–6
 - beta-adrenoceptor antagonists 55–6
 - corticosteroids 52–3
 - cyclosporin 53–4
 - see also* Drug abuse
- Dubowitz scoring system 1
- Dubowitz syndrome 23
- Dysostoses 23
- Electrical gradients 171
- Endangitis obliterans 40
- Enderteritis obliterans 140, 192
- Endocytosis 172

- Endothelin 112
- Environmental factors, in fetal growth 79–80
- Epidermal growth factor receptor 111
- Epstein-Barr virus 40
- Evidence-based management 401–16
- application to individual patients 414
 - Bayes' theorem and likelihood ratios 404–6
 - clinical trials 407–12
 - matching 408
 - meta-analysis 412
 - randomised controlled trials 408
 - reasons for 407–8
 - sources of bias 409–10
 - statistical problems of 410–11
 - of therapy 412
 - effective treatment 407
 - gold standards 402
 - GRIT study 412–14
 - test evaluation summary 407
 - tests and interpretation 402, 404
 - treatment paradox 402–4
 - variation of cut-off values 406–7
- Exocytosis 172
- Experimental models of fetal growth 81–5
- programming and critical periods of development 81–5
 - duration and severity of insult 85–6
 - timing of insult 82–5
 - type of insult 82
 - species 81
- Extended Wigglesworth classification 323
- Extracellular matrix 91–3
- Extraembryonic mesoderm 12
- differentiation of 392–3
- Extravillous trophoblast 89–90
- proliferative 117–18
 - cell islands 117
 - chorionic plate 118
 - smooth chorion 118
 - subtypes and stages 90
 - see also* Uteroplacental circulation
- Facilitated diffusion 171
- Factor V Leiden 300, 301, 329–30
- Factors associated with IUGR 307, 360–2
- alcohol 361
 - congenital anomalies and infections 360
 - famine 360
 - multiple pregnancy 360–1
 - pre-eclampsia 361–2
 - smoking 361
- Famine 360
- Fanconi syndrome 23
- Femur length 211
- Fetal alcohol syndrome 61
- Fetomaternal haemorrhage 248
- Fetoplacental blood flow, improvement of 315–16
- Fetus
- abdominal size 209
 - abnormalities 193
 - and high maternal AFP 240
 - and high maternal HCG 244
 - alcohol effects on 61
 - anteartum death 323–35
 - after delivery and follow-up 332
 - investigations 328–32
 - cytogenetics 330
 - placental pathology 331–2
 - postmortem 330–1
 - thrombophilia screening 329–30
 - obstetric management 324–8
 - Caesarean section 328
 - complications 325–6
 - induction of labour 326–8
 - timing of delivery 325
 - twin intrauterine death 328
 - asphyxia 172
 - asymmetry 266, 342
 - biparietal diameter 208–9, 210
 - blood pH 356–7
 - blood sampling 24, 37–8
 - carbon monoxide effects on 59
 - circulation 225–30
 - blood flow velocity 226
 - blood volume flow 225–6
 - cerebral circulation 230
 - descending aorta 228–9
 - Doppler waveform analysis 227–8
 - umbilical artery 229
 - crown-rump length 8–9, 208, 209
 - femur length 211
 - growth 377–8
 - assessment 218–19
 - determinants of 73–80, 376
 - endocrine/paracrine factors 75–9
 - environmental factors 79–80
 - genetic factors 79
 - infection 79
 - nutrients 73–5
 - plurality 79
 - temperature 79
 - experimental measurement of 80
 - intergenerational effects on 378
 - haematocrit 173–4
 - haemoglobin 173
 - head circumference 2, 357
 - heart rate 279–81
 - hypoxia 194
 - monitoring 263
 - during steroid administration 265
 - heart rate 279–81
 - papyraceous 328
 - placental perfusion 192–3
 - programming 376–80
 - size assessment 216–17
 - viability of 260–2
 - virus effects on 31
 - weight, serial ultrasound estimates 3
- Fibroblast growth factor 112

- Fibronectin 99–100
 as marker of fetoplacental growth restriction 250–1
- Fructose 75
- Ganciclovir 38
- Gap junctions 114
- Gelatinase 106
- Genetic factors, and fetal growth 79
- Gestational age assessment 206–8
- Glucose 74–5
 placental transfer 176–7
- Glyceryl trinitrate, in treatment of IUGR 315–16
- Gold standards 402
- Grannum grading system 266
- Growth factors 109–13
 angiogenic 151–9
 angiopoietins 158–9
 angiotensin II 112
 endothelin 112
 epidermal growth factor receptor 111
 fibroblast growth factor 112
 hemopoietic colony-stimulating factors 112
 insulin-like growth factors 111
 as marker of fetoplacental growth restriction 250–1
 placenta-like growth factor 138–9, 151–8
 Tie-2 158–9
 transforming growth factors 109–10
 in treatment of IUGR 314–15
 tumour necrosis factor alpha 112–13
 vascular endothelial growth factor 110–11, 151–8
- Growth Restriction Intervention Trial (GRIT) 275, 412–14
- Head circumference 2
- HELLP syndrome 240, 262, 269
- Hematopoiesis 133
- Hemopoietic colony-stimulating factors 112
- Henderson-Hasselbach equation 174–5
- High blood pressure *see* Hypertension; Pre-eclampsia
- Hormones
 fetal, and adult disease 373–5
 and fetal growth 75–9
 cortisol 76–7
 insulin 76
 insulin-like growth factors 77–8
 pituitary hormones 77
 thyroid hormones 76
- Human chorionic gonadotrophin 114, 243–9
 biology 243–4
 high maternal
 and diseases of pregnancy 244–7
 and fetal anomalies 244
 pathophysiology 247
- Human immunodeficiency virus 43–5
 treatment 45
- Hydatidiform mole 115
- Hypercapnia 174–5
- Hyperplasia 7
- Hypertension
 in adulthood, and fetal growth 369–70
 maternal, and IUGR 293
see also Pre-eclampsia
- Hypertrophy 7
- Hypoaminoacidaemia 177–80
- Hypoglycaemia 176–7, 340, 341
- Hypoxaemia 172–4
- Hypoxia
 postplacental 162
 preplacental 161
 uteroplacental 161–2
- Immunoglobulins 93, 95
- Infections
 and fetal growth 79
 viral 29–49
 cytomegalovirus 32–9
 effects on fetus 31
 human immunodeficiency virus 43–5
 mechanisms of infection 30
 rubella 39–41
 tests for 31
 varicella-zoster 42–3
 virus properties 30
- Inhibins 115
 as marker of fetoplacental growth restriction 251
- Inner cell mass 12
 mosaic abnormality of 12
- Insulin, and fetal growth 76
- Insulin resistance, in adulthood, and fetal growth 369–70
- Insulin-like growth factors 77–8, 111
- Integrins 95–7
 switching in cytotrophoblast invasion 99–101
- Intermediate trophoblast 89
- Internet 417–23
 anatomy of 418–19
 history of 417–18
 medical informatics 417
 milestones of 418
 websites 419–23
 Centre for Evidence-based Medicine 421
 Health Information Research Unit 421–3
 Health On the Net 420
 Online Mendelian Inheritance in Man 420–1
- Interstitial collagenase 105–6
- Intravascular extravillous cytotrophoblast 190
- Isoferritin 252
- Johanson-Blizzard syndrome 23
- Killer activatory receptors 116

- Killer inhibitory receptors 116
 Knockout mice 387–8, 395
- Labour and delivery
 Caesarean section 286–8
 antepartum fetal death 328
 induction of labour 257–8, 284–6
 antepartum fetal death 326–8
 mifepristone 326–7
 misoprostol 327–8
 prostaglandins 326
 outcome in small fetus 275–7
 procedures for delivery 269
 route of delivery 268–9
 timed delivery 264, 318
 antepartum fetal death 325
- Lactate 75
- Lactation, inhibition of 332
- Laminins 92–3
- Late gestation IUGR 275–92
 antepartum tests 277–84
 amniotic fluid volume 277–8
 biophysical profile score 281–2
 Doppler ultrasound 282–4
 fetal heart rate monitoring 279–81
 Caesarean section 286–7
 rates and complications 286–7
 in small fetus 287
 induction of labour 284–6
 methods and outcome 284
 in small fetus 284–6
 outcome of labour 275–7
 antepartum tests and 277–84
- Leprechaunism 23
- Leukaemia inhibitory factor 108
- Lifestyle factors 64–5
 physical activity 65
 socioeconomic status and poverty 64–5
- Likelihood ratios 404–6
- Lipids 75
- Lupus anticoagulant 298
- Magnetic resonance imaging 2
- Major histocompatibility complex 115–17
- Maternal
 AFP 240–2
 anaemia 340, 341
 and IUGR 293
 asthma, and IUGR 293
 body composition 379–80
 cardiac disease, and IUGR 293
 diabetes, and IUGR 293
 disease 293–306
 anaemia 293
 asthma 293
 cardiac disease 293
 diabetes 293
 hypertension 293
 pre-eclampsia *see* Pre-eclampsia
 thrombophilias 297–301
 antiphospholipid autoantibodies 298–9
 proteins of coagulation 299–301
 thyrotoxicosis 293
 haemodilution 318
 HCG, and Down's syndrome 244
 hypertension, and IUGR 293
 nutrition 80, 309–11, 376–7
 and body composition 379–80
 and fetal growth 80, 309–11
 and fetal programming 376–7
 tissue specific effects 379
 size 80
 uniparental disomy 15
- Matrilysin 106
- Medical informatics 417
- Metabolic adaptation 342–3
- Metalloproteinases 105–7
- Microvillous plasma membrane 168
- Mifepristone, in induction of labour 326–7
- Misoprostol, in induction of labour 327–8
- Monosomy X 10
- Mortality, infant 339–40, 353
- Mosaicism 10
 confined placental 10–18
- Multiple pregnancy 260–1
 and fetal growth 79
 twins 328
- National Collaborative Perinatal Project 355
- Necrotising enterocolitis 340, 343–4
- Neonate
 complications
 anaemia 340, 341
 hypoglycaemia 340, 341
 necrotising enterocolitis 340, 343–4
 perinatal hypoxia 340
 polycythaemia 340, 341
 postnatal growth 340
 respiratory distress syndrome 340, 341, 344–5
 complications in 337–49
 condition at birth and resuscitation 338–9
 cytomegalovirus in 35, 37
 growth over first year 346
 metabolic adaptation 342–3
 morphology 2
 mortality 339–40
 see also Paediatric implications of IUGR
- Neu-Laxova syndrome 23
- Neurodevelopmental disability 359
- Nicotine *see* Smoking
- Nitric oxide 113–14, 315
- Non-branching angiogenesis 150–1
- Non-stress testing 279
- Nutrients 73–5
 amino acids 75
 carbohydrates 74–5
 lipids 75
 oxygen 74

- Nutrition
 maternal 80, 376–7
 parenteral 310–11
- Obesity, maternal 380
- Obstetric Classification 323
- Obstetrician, postnatal role of 269–70
- Odds ratios 411
- Oestriol, unconjugated 250
- Oligohydramnios 20, 276, 277, 278
- Opiates, effects on fetal growth 61–2
- Osteogenesis imperfecta 23
- Oxygen 74
 and placental development 160–2
 postplacental hypoxia 162
 preplacental hypoxia 161
 uteroplacental hypoxia 161–2
 placental transfer 172–4
 therapy of IUGR 313–14
- Oxygen tension 104–5
- Oxytocin contraction stress test 284
- Paediatric implications of IUGR 351–66
 case-control studies 359–60
 cerebral palsy 359–60
 neurodevelopmental disability 359
 cohort studies of term infants 354–7
 IUGR defined by size 354–5
 IUGR defined by size-independent
 criteria 355–7
 cohort studies of very preterm infants
 357–9
 criteria for inference 351
 intermediate factors 362–3
 in neonate *see* Neonate
 potential confounders 351–4
 cause of growth restriction 353
 control for causal factors 353–4
 control for gestational duration
 inadequacy of 352
 in preterm infants 352
 matching for birthweight 352
 mortality 353
 selecting cohorts using birthweight
 criteria 351–2
 systematic differences in perinatal care
 352–3
 risk of impairment and cause 362
 specific causes of IUGR 360–2
 alcohol 361
 congenital anomalies and infections 360
 famine 360
 multiple pregnancy 360–1
 pre-eclampsia 361–3
 smoking 361
- Paracellular diffusion 170–1
- Parenteral nutrition 310–11
- Paternal uniparental disomy 15
- Perinatal hypoxia 340
- Perinatal viral infections 29–49
 cytomegalovirus 32–9
 effects on fetus 31
 human immunodeficiency virus 43–5
 mechanisms of infection 30
 rubella 39–41
 tests 31
 varicella-zoster 42–3
 virus properties 30
- Phenylketonuria 311
- Physical activity, and IUGR 65, 312
- Pituitary hormones, and fetal growth 77
- Placenta
 abnormalities of 267
 acidosis 176
 advanced maturation 266
 amino acid transfer 177–80
 confined placental mosaicism 10–18,
 395–6
 in cytomegalovirus infection 36
 development
 early phase 131–2
 genes involved in 396
 molecular regulation of 391–6
 extraembryonic mesoderm
 differentiation 392–3
 modulation by maternal factors
 394–5
 trophoblast differentiation 391–2
 trophoblast invasiveness 392
 trophoblast-mesoderm interactions
 393
 vascular development 393–4
 origins of IUGR during 390–1
 stages of 387–9
 glucose transfer 176–7
 growth of 378–9
 hypoamnoacidaemia 177–80
 hypoxia 194
 infarction 267
 IUGR in 259
 late gestation 265–8
 viable early onset 262
 jelly-like 249
 molecular targets in 395–6
 confined placental mosaicism 395–6
 knockout mouse studies 395
 morphology 223
 nicotine effects on 58
 pathology 187–201
 anteartum fetal death 331–2
 cytogenetic abnormalities 193
 fetal perfusion 192–3
 gross abnormalities 188–9
 histological abnormalities 189–90
 maternal perfusion 190–2
 placental size 188
 SGA infants 187
 proton transfer 176
 size 188
 smoking effects on 58
 in triploidy 9
 ultrasound 267

- Placenta—*continued*
 villi *see* Placental villi
see also Placental; Uteroplacental circulation
- Placenta percreta 115
- Placenta-like growth factor 138–9
- Placental angiogenesis 149–65
 angiogenic growth factors 151–9
 branching angiogenesis 150
 non-branching angiogenesis 150–1
 oxygen effects on 160–2
 postplacental hypoxia 162
 preplacental hypoxia 161
 uteroplacental hypoxia 161–2
 vasculogenesis 149–50
- Placental hyperoxia 141
- Placental infarction 188–9
- Placental insufficiency 187
- Placental perfusion
 fetal 192–3
 maternal 190–2
- Placental transfer 167–86
 amino acids and hypoaminoacidaemia 177–80
 anatomy and morphology 168
 carbon dioxide and hypercapnia 174–5
 drug abuse and 181
 fetal asphyxia 172
 glucose and hypoglycaemia 176–7
 oxygen and hypoxaemia 172–4
 proton transfer and acidosis 176
 solute transfer across syncytiotrophoblast 168–72
 diffusion 169–71
 endocytosis and exocytosis 172
 transporter protein-mediated transfer 171
- Placental villi 131–47
 development of 131–9
 gas-exchanging villi 138–9
 implantation 131
 initial 131–4
 tertiary villi 134–8
 gas-exchanging 138–9, 141–4
 immature intermediate 134
 intussusception of 138
 maldevelopment in IUGR 139–44, 189
 gas-exchanging villi 141–4
 stem arteries 139–41
 umbilical cord 139
 mature intermediate 138
 primary 131–2
 secondary 132
 tertiary 132, 134–8
- Plasminogen activators 107–9
- Plurality, and fetal growth 79
- Polycystic ovary syndrome, following IUGR 372–3
- Polycythaemia 340, 341
- Polymerase chain reaction 31
- Polymorphism 12–13
- Ponderal index 2, 221
- Postmortem, in antepartum fetal death 330–1
- Postplacental hypoxia 162
- Poverty 64–5
- Prader-Willi syndrome 21
- Pre-eclampsia 103–4, 140, 144
 bromocriptine not recommended in 332
 and high maternal AFP 240, 242
 and high maternal HCG 244
 and IUGR 294–7, 361–2
 outpatient screening 262
 pathogenesis 294–5
see also Hypertension
- Pregnancy
 cigarette smoking in 57
 diseases of
 and high maternal AFP 240–2
 and high maternal HCG 244–7
 length of 352
 normal 206
 management in drug addicts 63–4
- Preplacental hypoxia 161
- Preterm infants
 cohort studies 357–9
 gestational duration in 352
- Prevention and treatment of IUGR 307–21
 antenatal care 308–9
 dietary supplementation 309–11
 drug abuse during pregnancy 311–12
 physical activity 312
 antenatal treatment 312–17
 abdominal decompression 316–17
 antenatal corticosteroids and timed delivery 317
 growth factors 314–15
 improvement of fetoplacental blood flow 315–16
 low dose aspirin 312–13
 maternal haemodilution 317
 oxygen therapy 313–14
 primary prevention 308
 secondary prevention 308
 tertiary prevention 308
 trials of therapy 412
- Project HUG 308
- Proliferating cell nuclear antigen 90
- Prostacyclin 250
- Prostaglandins, in induction of labour 326
- Protein C 300
- Protein S 300
- Proteinases 105–7
 gelatinase A 106
 gelatinase B 106
 interstitial collagenase 105–6
 matrilysin 106
 stromelysin-1 106
 stromelysin-3 106
 type IV collagenase 106
- Proto-oncogenes 113
- Protons, placental transfer 176

- Randomised controlled trials 408
- Recreational drugs *see* Drug abuse
- Respiratory distress syndrome 340, 341, 344–5
- Rubella 39–41
 - congenital rubella syndrome 40
 - transmission of 39–40
 - vaccination 41
- Rubinstein-Taybi syndrome 23
- Screening
 - chromosome abnormalities 223
 - IUGR 309
 - pre-eclampsia 262
 - thrombophilia 329–30
 - ultrasound 223
- Seckel syndrome 23
- Selectins 95, 102–3
- Sex chromosome aneuploidies 18
- Shingles 42
- Silver-Russell syndrome 19, 23
- Simian immunodeficiency virus 45
- Skeletal muscle metabolism in fetus 373
- Small for gestational age infants 1, 187, 257–8
 - Caesarean section in 287–8
 - induction of labour 275–7, 284–6
 - ultrasound prediction 219–21
 - without risk factors 342
- Smoking 57–9
 - and carbon monoxide 59
 - cigarette smoking in pregnancy 57
 - effects on placental morphology 58
 - effects on uteroplacental circulation 58–9
 - evidence for IUGR 57–8, 361
 - placental transfer 181
 - and reduced risk of pre-eclampsia 296
- Social isolation 65
- Socioeconomic status 64–5
- Spalding's sign 324–5
- Spina bifida, and high maternal AFP 242
- Spongiotrophoblast 389
- Stem arteries 139–41
 - alterations in structure 140–1
 - reduced density of 140
- Steroids, fetal monitoring during
 - administration 263
- Stromelysins 106
- Structural abnormalities 8–9, 18
- Syncytial knots 192
- Syncytiotrophoblast 11, 168
 - development of 388–9
 - solute transfer across 168–72
 - diffusion 169–71
 - endocytosis and exocytosis 172
 - transporter protein-mediated transfer 171–2
- Syndromes 23
 - see also individual syndromes*
- Temperature, and fetal growth 79
- Tenascin 100
- Tetraploidy 18
- Thanatophoric dysplasia 23
- Therapeutic drugs *see* Drugs
- Thrombophilias, maternal, and IUGR 297–301
 - antiphospholipid autoantibodies 298–9
 - proteins regulating coagulation 299–301
 - screening for 329–30
- Thyroid hormones, and fetal growth 76
- Thyrototoxicosis, maternal, and IUGR 293
- Tie-2 158–9
- Tissue inhibitors 107
- Townes-Brock syndrome 19
- Transforming growth factors 109–10
- Transporter protein-mediated transfer 171
- Treatment of IUGR 312–17
 - abdominal decompression 316–17
 - antenatal corticosteroids and timed delivery 317
 - evidence-based *see* Evidence-based management
 - growth factors 314–15
 - improvement of fetoplacental blood flow 315–16
 - low dose aspirin 31–13
 - maternal haemodilution 317
 - oxygen therapy 313–14
- Triploidy 9, 258
 - and high maternal HCG 244
- Trisomies 8–9, 21–2, 258, 395
 - correction of 14, 15, 16, 22
 - see also individual trisomies*
- Trisomy 2 20
- Trisomy 7 19–20
- Trisomy 13 258
- Trisomy 15 21
- Trisomy 16 18–19
- Trisomy 18 258
- Trisomy 21 258
- Trisomy 22 258
- Trophoblast 11
 - development of 389
 - differentiation 391–2
 - endovascular 98
 - extravillous *see* Extravillous trophoblast
 - intermediate 89
 - invasion 97–9, 392
 - mosaic abnormality of 12
 - routes of differentiation 119
- Tumour necrosis factor alpha 112–13
- Turner syndrome 10
- Twin intrauterine death 328
- Twin to twin transfusion syndrome 328
- Ultrasound 205–38
 - amniotic fluid 223–4
 - appropriate reference ranges 212–16
 - assessment of fetal growth 218–19
 - assessment of fetal size 216–17
 - assessment of gestational age 206–8
 - biometry

Ultrasound—*continued*

- prediction of adverse outcome 221–3
 - prediction of small infants 219–21
 - diagnosis of IUGR by 3–4
 - Doppler
 - antepartum assessment 282–4
 - blood flow velocity 226
 - blood volume flow 225–6
 - cerebral circulation 230
 - descending aorta 228–9
 - fetal circulation 225–30
 - middle cerebral artery 266
 - umbilical artery 132, 229–30, 265–6, 283, 403
 - umbilical cord 132
 - uterine artery 230–1, 266
 - waveform analysis 227–8
 - fetal weight 3
 - measurements
 - abdominal size 209–10
 - crown-rump length 208
 - femur length 211
 - precision of 211–12
 - size of head 208–9
 - normal length of pregnancy 206
 - placental morphology 223
 - screening for malformations 223
 - uterine artery velocimetry 230–1
 - Umbilical cord
 - blood flow, Doppler measurement 355–6
 - in IUGR 139
 - umbilical artery Doppler 132, 229–30, 265–6, 283, 403
 - Uniparental disomy 10–18
 - Uterine artery velocimetry 230–1
 - Uteroplacental circulation 89–129
 - activators 107–9
 - activins and inhibitors 115
 - blood group antigens 117
 - cell adhesion molecules 91–7
 - caherins 93
 - expression by cytotrophoblast 102–3
 - extracellular matrix 91–3
 - immunoglobulins 93, 95
 - integrins 95–7
 - selectins 95
 - in trophoblast invasion 97–9
 - extravillous trophoblast 89–90
 - gap junctions and connexins 114
 - growth factors 109–13
 - angiotensin II 112
 - endothelin 112
 - epidermal growth factor receptor 111
 - fibroblast growth factor 112
 - hemopoietic colony-stimulating factors 112
 - insulin-like growth factors 111
 - transforming growth factors 109–10
 - tumour necrosis factor alpha 112–13
 - vascular endothelial growth factor 110–11
 - human gonadotrophin 114
 - improvement of 315–16
 - major histocompatibility complex 115–17
 - nitric oxide 113–14
 - oxygen tension 104–5
 - pre-eclampsia 103–4
 - proliferation markers 90–1
 - proliferative extravillous trophoblast 117–18
 - cell islands 117
 - chorionic plate 118
 - smooth chorion 118
 - proteinases 105–7
 - routes of trophoblast differentiation 119
 - smoking effects on 58–9
 - switching of integrin repertoires 99–101
 - tissue inhibitors 107
- Uteroplacental hypoxia 161–2
- Vanishing twin syndrome 328
- Varicella-zoster immunoglobulin 43
- Varicella-zoster virus 42–3
- Vascular endothelial growth factor 58, 110–11, 151–8
- Vasculogenesis 132, 149–50
- Vasculosyncytial membrane 139, 156
- Villi
 - gas-exchanging 138–9
 - in IUGR 141–4
 - immature intermediate 134
 - mature intermediate 138–9
 - placental *see* Placental villi
 - primary 131–2
 - secondary 132
 - tertiary 132
 - differentiation and development 134–8
 - tertiary stem 133
- Villitis 189–90
- Vimentin 136
- Viral infections *see* perinatal viral infections
- Viruses
 - capsomere 30
 - effects on fetus 31
 - mechanism of infection 30
 - nucleocapsid 30
 - properties 30
 - tests for 31
 - virion 30
 - see also* Perinatal viral infections
- Volatile substances, effects on fetal growth 63
- Zidovudine 45
- Zonula adherens junctions 93